A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PANACEA
- 07 Jun 2017 Biomarkers information updated
- 29 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
- 29 May 2017 Status changed from recruiting to active, no longer recruiting.